Pharmacologic Treatment for Temporomandibular and Temporomandibular Joint Disorders
Published by Elsevier Inc..
Temporomandibular joint disorder is defined by pain and/or loss of function of the temporomandibular joint and its associated muscles and structures. Treatments include noninvasive pharmacologic therapies, minimally invasive muscular and articular injections, and surgery. Conservative therapies include nonsteroidal anti-inflammatory drugs, muscle relaxants, benzodiazepines, antidepressants, and anticonvulsants. Minimally invasive injections include botulinum toxin, corticosteroids, platelet-rich plasma, hyaluronic acid, and prolotherapy with hypertonic glucose. With many pharmacologic treatment options and modalities available to the oral and maxillofacial surgeon, mild to moderate temporomandibular joint disorder can be managed safely and effectively to improve symptoms of pain and function of the temporomandibular joint.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Oral and maxillofacial surgery clinics of North America - 34(2022), 1 vom: 22. Feb., Seite 49-59 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Andre, Amanda [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9004-61-9 |
|---|
| Anmerkungen: |
Date Completed 23.11.2021 Date Revised 23.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.coms.2021.08.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331401789 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331401789 | ||
| 003 | DE-627 | ||
| 005 | 20231225213400.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.coms.2021.08.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1104.xml |
| 035 | |a (DE-627)NLM331401789 | ||
| 035 | |a (NLM)34598856 | ||
| 035 | |a (PII)S1042-3699(21)00060-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Andre, Amanda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacologic Treatment for Temporomandibular and Temporomandibular Joint Disorders |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.11.2021 | ||
| 500 | |a Date Revised 23.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published by Elsevier Inc. | ||
| 520 | |a Temporomandibular joint disorder is defined by pain and/or loss of function of the temporomandibular joint and its associated muscles and structures. Treatments include noninvasive pharmacologic therapies, minimally invasive muscular and articular injections, and surgery. Conservative therapies include nonsteroidal anti-inflammatory drugs, muscle relaxants, benzodiazepines, antidepressants, and anticonvulsants. Minimally invasive injections include botulinum toxin, corticosteroids, platelet-rich plasma, hyaluronic acid, and prolotherapy with hypertonic glucose. With many pharmacologic treatment options and modalities available to the oral and maxillofacial surgeon, mild to moderate temporomandibular joint disorder can be managed safely and effectively to improve symptoms of pain and function of the temporomandibular joint | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Botox | |
| 650 | 4 | |a Intra-articular injections | |
| 650 | 4 | |a Pharmacotherapy | |
| 650 | 4 | |a Prolotherapy | |
| 650 | 4 | |a TMD | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a Hyaluronic Acid |2 NLM | |
| 650 | 7 | |a 9004-61-9 |2 NLM | |
| 700 | 1 | |a Kang, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Dym, Harry |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oral and maxillofacial surgery clinics of North America |d 1996 |g 34(2022), 1 vom: 22. Feb., Seite 49-59 |w (DE-627)NLM089672305 |x 1558-1365 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2022 |g number:1 |g day:22 |g month:02 |g pages:49-59 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.coms.2021.08.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2022 |e 1 |b 22 |c 02 |h 49-59 | ||